Vidac Pharma publishes results of next-generation drug candidate tests in human and murine tumor models
July 25, 2024 01:30 ET
|
Vidac Pharma Holding PLC
London (UK), July 25, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel...
Non-Hodgkin Lymphoma Therapeutics Market revenue to hit USD 20 Billion by 2036, says Research Nester
March 19, 2024 07:00 ET
|
Research Nester
New York , March 19, 2024 (GLOBE NEWSWIRE) -- The global non-hodgkin lymphoma therapeutics market size is projected to grow at a CAGR of over 8% from 2024 to 2036. The market is expected to garner a...
Global T-Cell Lymphoma Market Size to grow USD 3390.6 Million by 2030 | CAGR of 8.50%
November 08, 2022 13:00 ET
|
SPHERICAL INSIGHTS LLP
New York, United States , Nov. 08, 2022 (GLOBE NEWSWIRE) -- According to a research report published by Spherical Insights & Consulting, the Global T-Cell lymphoma market size to grow from USD...
Global T-cell Lymphoma Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight
May 31, 2022 13:00 ET
|
DelveInsight Business Research LLP
Las Vegas, USA, May 31, 2022 (GLOBE NEWSWIRE) -- Global T-cell Lymphoma Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight T-cell Lymphoma Pipeline constitutes...
Kura Oncology Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma
December 13, 2021 10:30 ET
|
Kura Oncology, Inc.
– Overall response rate of 56% and median overall survival of 32.8 months in patients with advanced AITL, an aggressive form of T-cell lymphoma – – Results presented at ASH underscore potential of...
Devimistat (CPI-613®) to be Explored in a New Combination for T-Cell Lymphoma Treatment as Part of Stand Up To Cancer’s T-Cell Lymphoma “Dream Team Research Grant”
February 07, 2019 08:55 ET
|
Rafael Pharmaceutical Inc.
Newark, NJ, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that...
Rafael Pharmaceuticals Receives FDA Orphan Drug Designation of CPI-613 for the Treatment of Peripheral T-Cell Lymphoma (PTCL)
August 16, 2018 10:55 ET
|
Rafael Pharmaceutical Inc.
Newark, NJ, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that the U.S. Food and Drug...
Rafael Pharmaceuticals Announces Activation of Second Clinical Trial Site for the Phase I Study of CPI-613 in Patients with Relapsed or Refractory T-Cell Lymphoma
August 13, 2018 11:15 ET
|
Rafael Pharmaceutical Inc.
Newark, NJ, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced the activation of a second clinical...
Rhizen Pharmaceuticals S.A. Announces Presentations on Tenalisib (RP6530) at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
May 29, 2018 07:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, May 29, 2018 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., a clinical-stage biotechnology company developing Tenalisib (RP6530), a highly selective and orally...
Rhizen Pharmaceuticals S.A. receives FDA Fast Track Designation for Tenalisib (RP6530), a highly selective dual PI3K delta/gamma inhibitor for the treatment of patients with relapsed and/or refractory Cutaneous T-cell Lymphoma (CTCL)
April 13, 2018 07:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, April 13, 2018 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation...